Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
August 29, 2022 08:00 ET
|
Daré Bioscience, Inc.
Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If clinical development is successful, Sildenafil Cream,...
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
August 24, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin...
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
August 09, 2022 08:00 ET
|
Daré Bioscience, Inc.
June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license...
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
August 02, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
July 07, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will...
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
June 30, 2022 08:00 ET
|
Daré Bioscience, Inc.
Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience,...
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
June 24, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced partial adjournment of its 2022 Annual Meeting of...
Daré Bioscience to Participate in the 2022 BIO International Convention
June 06, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
May 16, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
May 12, 2022 06:00 ET
|
Daré Bioscience, Inc.
$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for...